von Willebrand factor — Competitive Intelligence Brief

von Willebrand factor (von Willebrand factor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Coagulation factor replacement. Area: Hematology.

marketed Coagulation factor replacement Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site Hematology Small molecule

Target snapshot

von Willebrand factor (von Willebrand factor) — National Center for Research Resources (NCRR). Von Willebrand factor (vWF) is a blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for clotting factor VIII.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
von Willebrand factor TARGET	von Willebrand factor	National Center for Research Resources (NCRR)	marketed	Coagulation factor replacement	Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site
Factor IX recovery	Factor IX recovery	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Coagulation factor replacement	Factor IX (coagulation factor IX)
Recombinant Human Coagulation FVIII	Recombinant Human Coagulation FVIII	Sinocelltech Ltd.	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII
Fibrinogen + PCC	Fibrinogen + PCC	University Health Network, Toronto	marketed	Hemostatic agent / Coagulation factor replacement
OctaplasLG®	OctaplasLG®	Rigshospitalet, Denmark	marketed	Plasma product; coagulation factor replacement	Multiple coagulation factors (I, II, V, VII, VIII, IX, X, XI, XII)
FIX	FIX	Bioverativ Therapeutics Inc.	marketed	Recombinant coagulation factor replacement	Factor IX (coagulation cascade)
Coagulation Factor VIII	Coagulation Factor VIII	Beijing Children's Hospital	marketed	Coagulation factor replacement	Coagulation Factor VIII (antihemophilic factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Coagulation factor replacement class)

1. Beijing Children's Hospital · 1 drug in this class
2. Bioverativ Therapeutics Inc. · 1 drug in this class
3. Hoffmann-La Roche · 1 drug in this class
4. National Center for Research Resources (NCRR) · 1 drug in this class
5. Takeda · 1 drug in this class
6. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class